Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals

First Page		Document Content
Date: 2005-10-17 17:55:35 Health Cardiac electrophysiology Pharmacology Ion channels Syndromes HERG QT interval Long QT syndrome Torsades de pointes Biology Cardiac dysrhythmia Medicine		Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 51,75 KB Share Document on Facebook

	healthbank Charter At healthbank we hold the following core values as inalienable : 1. Our users have the right to own and control their health data. 2. Our users have the option to share their data with health care prof DocID: 1xVXh - View Document
	For more information, visit: www.caci.com/Health Health CACI supports the Department of Defense and civilian health agency DocID: 1xVSv - View Document
	PRESS RELEASE Zurich, Best of both worlds in health science Advancience and healthbank The data science company, started as a spin-off project of Basel University, together with the GDPR compliant health data p DocID: 1xVQI - View Document
	COLOR GENOMICS, INC. NOTICE OF PRIVACY PRACTICES THIS N OTICE D ESCRIBES H OW M EDICAL I NFORMATION A BOUT Y OU THAT IS PROTECTED UNDER THE HEALTH DocID: 1xVPn - View Document
	Assignment 2 Stata Exercise For the following questions, use the Virginia Health dataset posted on the class web page. The dataset contains survey information from Virginia residents in the yearThese DocID: 1xVLI - View Document